Preclinical data suggests AOD9604 shifts the metabolic balance toward burning fatty acids for energy rather than storing them, with effects observed particularly in visceral adipose tissue
By stimulating the body's own growth hormone production, CJC 1295 supports muscle development, enhances metabolic function, and promotes more effective recovery processes
This guidance follows the FDAs approval of Wegovy (semaglutide) for an expanded indication to reduce the risk of major cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in adults with established cardiovascular disease (CVD) and who are either obese or overweight
[DOI] [PubMed] [Google Scholar] 202.Shami GJ, Cheng D, Verhaegh P, Koek G, Wisse E, Braet F